TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15536108
Drug: Enalapril, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 20 mg
Study: 3118453
Drug: Oral phenoxymethylpenicillin
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phenoxymethylpenicillin 2 g every 8 h, reduced to 1 g every 8 h after normalization of temperature.
Study: 3118453
Drug: Intravenous benzylpenicillin
Normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous benzylpenicillin 3 g every 8 h, reduced to oral phenoxymethylpenicillin 1 g every 8 h after normalization of temperature.
Study: 31504461
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal treatment (IPT; sub- and supragingival scaling/chlorhexidine; n=50)
Study: 31504461
Drug: Control periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control periodontal treatment (CPT; supragingival scaling; n=51)
Study: 7960981
Drug: Adjunctive irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive irradiation after excision of primary lesions plus limited neck dissection (n = 32)
Study: 7960981
Drug: Adjunctive radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive radiotherapy
Study: 28520955
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.3 mg) + bupivacaine (10 mg)
Study: 28520955
Drug: Intrathecal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ketamine (0.1 mg/kg) + bupivacaine (10 mg)
Study: 28520955
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.3 mg) + ketamine (0.1 mg/kg) + bupivacaine (10 mg)
Study: 22014541
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice weekly (BIW) for 12 weeks, followed by etanercept 50 mg once weekly (QW)
Study: 22014541
Drug: SC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC placebo BIW for 12 weeks, followed by etanercept 50 mg BIW for 12 weeks
Study: 17389703
Drug: High-dose propylthiouracil
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose propylthiouracil (PTU)
Study: 10639692
Drug: Four 3-g
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 3-g glucose tablets
Study: 10639692
Drug: Four matched
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four matched placebo tablets
Study: 7488817
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with multiple low doses of porcine surfactant
Study: 7488817
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy
Study: 1935927
Drug: Propofol (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (bolus 1.5 mg kg‐1, infusion 9 mg kg‐1 h‐1 for 10 min thereafter 6 mg kg‐1 h‐1)
Study: 1935927
Drug: Etomidate (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (bolus 0.10 mg kg‐1, infusion 3 mg kg‐1 h‐1 reduced to 0.6 mg kg‐1 h‐1)
Study: 7047681
Drug: ADW hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADW hepatitis B vaccine
Study: 7047681
Drug: AYW hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: AYW hepatitis B vaccine
Study: 12150684
Drug: Broad-spectrum antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antifungal agents (new agents with enhanced activity against non-C. albicans and Aspergillus species)
Study: 12150684
Drug: Reformulated older
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated older broad-spectrum antifungals
Study: 2201960
Drug: Theophylline (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (15-20 mg/L)
Study: 835370
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 6-propylthiouracil (PTU) in a fasting state
Study: 835370
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 6-propylthiouracil (PTU) with a standardized breakfast
Study: 19054187
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including pain assessment at rest and with physical therapy, physician protocols for standing analgesia and preemptive analgesia before PT.
Study: 11354236
Drug: Milnacipran 50
Normalized name: milnacipran 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 50 mg b.d. for 6 weeks
Study: 11354236
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg b.d. for 6 weeks
Study: 2107653
Drug: GHRH (1‐29)
Normalized name: GHRH(1-44)
DrugBank: Somatorelin (DB12656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1‐29) NH2, 100 micrograms plus cortisone acetate 25 mg
Study: 2107653
Drug: GHRH (1‐29)
Normalized name: GHRH(1-44)
DrugBank: Somatorelin (DB12656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1‐29) NH2, 100 micrograms plus cortisone acetate 50 mg
Study: 25911562
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen sodium (180 mg/day)
Study: 23369024
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg/day)
Study: 23618777
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion (3 μg kg(‐1) h(‐1) reduced to 1.5 μg kg(‐1) h(‐1) after reperfusion for 3 postoperative days)
Study: 17693684
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron injections
Study: 11776302
Drug: Dalteparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5,000 IU anti‐Xa once daily
Study: 11776302
Drug: Enoxaparin 4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 4,000 IU anti‐Xa once daily
Study: 11776302
Drug: Tinzaparin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 50 IU/kg anti‐Xa (average dose 3,650 anti‐Xa units) once daily
Study: 6239670
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (applied relaxation and applied relaxation plus operant conditioning)
Study: 16864983
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (Premarin 0.625 mg)
Study: 16864983
Drug: Tibolone (Livial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (Livial 2.5 mg)
Study: 2251208
Drug: Yohimbine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (15 mg)
Study: 6127224
Drug: Dynorphin‐(1‐13) at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynorphin‐(1‐13) at a dose of 60 micrograms/kg body weight
Study: 28974553
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of allogenic UC‐MSCs (1×10^6 cells/kg)
Study: 28974553
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of allogenic UC‐MSCs
Study: 19942724
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic injection
Study: 17470161
Drug: Monthly i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly i.v. clodronate
Study: 17470161
Drug: Monthly i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly i.v. zoledronic acid
Study: 9487210
Drug: Valacyclovir (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (1000 mg twice daily for 5 days)
Study: 9487210
Drug: Acyclovir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (200 mg 5 times daily for 5 days)
Study: 8045141
Drug: HA-1A (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A (100 mg)
Study: 3059756
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of acetaminophen
Study: 23464813
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin
Study: 22269473
Drug: 10mg mifepristone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg mifepristone daily for 6 months
Study: 22269473
Drug: 5mg mifepristone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg mifepristone daily for 6 months
Study: 22269473
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up at 12 months
Study: 7541235
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with PBPC support and G-CSF (12 or 30 micrograms kg‐1 day‐1 for 10 days)
Study: 7541235
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with PBPC support and G-CSF
Study: 2386358
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene brachial plexus block with 0.75% bupivacaine (150‐210 mg) with adrenaline, followed by an infusion of 0.25% bupivacaine 0.25 mg/kg/h
Study: 2386358
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia after starting a continuous interscalene brachial plexus block with a test dose of 0.75% bupivacaine (22.5 mg) with adrenaline, followed by an infusion of 0.25% bupivacaine 0.25 mg/kg/h
Study: 514425
Drug: Glucose-enriched dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-enriched dialysate (400 mg/100 ml)
Study: 31263024
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with bevacizumab (15 mg/kg every 3 weeks for ≥3 cycles)
Study: 24682080
Drug: Continuous sciatic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sciatic nerve block (0.2% ropivacaine 5 mL/h)
Study: 24682080
Drug: Single-injection sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection sciatic nerve block (0.2% ropivacaine 20 mL) with sham continuous SNB (0.9% normal saline 5 mL/h)
Study: 15943172
Drug: Cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive group treatment program (10-week, 30 hours)
Study: 15943172
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment vs control at 18 months
Study: 10395845
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard therapy (2 nucleoside analogues and a protease inhibitor)
Study: 2182236
Drug: Anistreplase (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase (30 U administered intravenously within the first 6 hours)
Study: 23432528
Drug: Romiplostim (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (mean 5-8 μg/kg, self-administered at home)
Study: 21347869
Drug: High-dose selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose selenium supplementation (Se+ group, n = 75) - 1,000 μg on day 1, 500 μg/day on days 2-14
Study: 21347869
Drug: Standard selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard selenium dose (<75 μg/day) in control group (Se- group, n = 75)
Study: 19527280
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IVM) at 0.1 mg/kg
Study: 15613141
Drug: L-dopa therapy
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa therapy (as part of both interventions)
Study: 8551648
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 2 weeks (group II)
Study: 8551648
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum oral diet for 2 weeks (group I)
Study: 8551648
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 2 weeks (group IV)
Study: 23228946
Drug: Trisodium citrate,
Normalized name: Trisodium citrate, anhydrous
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trisodium citrate, 46.7%, locking solution (Citra-Lock)
Study: 20844946
Drug: Diaphragm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm and lubricant gel
Study: 16753156
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current dose of rFSH)
Study: 11578889
Drug: 1% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine, 0.2 mL/kg
Study: 11578889
Drug: 1.5% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine, 0.2 mL/kg
Study: 11578889
Drug: 2% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine, 0.2 mL/kg
Study: 11578889
Drug: 1% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine, 0.3 mL/kg
Study: 11578889
Drug: 2% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine, 0.3 mL/kg
Study: 9040451
Drug: Low blood
Normalized name: Glucagon Emergency Kit for Low Blood Sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low blood pressure goal for patients with urinary protein excretion > 1 g/d
Study: 7935657
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (12 g daily)
Study: 7935657
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil, similar dosage)
Study: 3281724
Drug: RTSC (cranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTSC (cranial irradiation and sequentially administered drug pairs)
Study: 31706622
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxide (Ca(OH)2) + Ibuprofen
Study: 28271228
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam syrup 0.5 mg/kg
Study: 28271228
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam spray 0.2 mg/kg
Study: 20457590
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg plus omeprazole
Study: 20457590
Drug: Atazanavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 400/100 mg plus omeprazole
Study: 19025944
Drug: Gadoversetamide (OptiMARK)
Normalized name: Gadoversetamide
DrugBank: Gadoversetamide (DB00538)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gadoversetamide (OptiMARK) at doses of 0.05, 0.1, 0.2, or 0.3 mmol/kg
Study: 17161766
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) doses (6.25 mg, 12.5 mg, or 25 mg) and extended release (ER) metoprolol doses (25 mg, 50 mg, 100 mg, 200 mg)
Study: 12705304
Drug: Immediate functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate functional loading of Brånemark System implants (development group)
Study: 12705304
Drug: 2-stage implants
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-stage implants (development group)
Study: 12705304
Drug: Simplified protocol
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified protocol (simplified treatment group)
Study: 1286503
Drug: Flumazenil (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (maximum dose, 30 ml providing 3 mg of flumazenil)
Study: 1286503
Drug: Placebo (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maximum dose, 30 ml)
Study: 31262379
Drug: Reslizumab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab 3.0 mg/kg every 4 weeks for 1 year
Study: 27521607
Drug: Trimethoprim/Sulfamethoxazole (TMP-SMZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/Sulfamethoxazole (TMP-SMZ) 160 mg/800 mg, 1 tablet twice daily for 45 days, then 1 tablet every 2 days for 311 days
Study: 27521607
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablet containing starch, no active ingredients), 1 tablet every 2 days for 311 days
Study: 24504700
Drug: Danirixin 50
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin 50 mg IR in fed state
Study: 24504700
Drug: Danirixin 50
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin 50 mg IR in fasted state
Study: 24504700
Drug: Bioenhanced Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioenhanced Formulation 1 in fasted state
Study: 24504700
Drug: Bioenhanced Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioenhanced Formulation 2 in fasted state
Study: 24504700
Drug: Bioenhanced formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioenhanced formulations
Study: 19942479
Drug: Chemotherapy (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (with cetuximab)
Study: 18171954
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of botulinum toxin A combined with hip abduction brace (6 hours/day)
Study: 12695416
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering therapy
Study: 12695416
Drug: No blood
Normalized name: VivaGuard Ino Blood Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: No blood pressure-lowering therapy
Study: 10824628
Drug: Almotriptan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan with verapamil (120‐mg sustained‐release verapamil tablet twice daily for 7 days and one 12.5‐mg almotriptan tablet on day 7)
Study: 10824628
Drug: Almotriptan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan alone (one 12.5‐mg almotriptan tablet on day 7)
Study: 8870755
Drug: Mannitol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (1 g/kg)
Study: 1505149
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 mg diazepam)
Study: 6356329
Drug: Bicozamycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicozamycin (500 mg, q.i.d. for 3 days)
Study: 6356329
Drug: Trimethoprim/sulphamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulphamethoxazole (160 mg TMP‐SMX 800 mg, b.i.d. for 5 days)
Study: 6356329
Drug: Trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (200 mg, b.i.d. for 5 days)
Study: 30851250
Drug: Overall implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall implant survival
Study: 30202072
Drug: Superonasal (SN)
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superonasal (SN) injection
Study: 30202072
Drug: Inferonasal (IN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferonasal (IN) injection
Study: 30202072
Drug: Superotemporal (ST)
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superotemporal (ST) injection
Study: 30202072
Drug: Inferotemporal (IT)
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferotemporal (IT) injection
Study: 26505342
Drug: High-dose interferon-α-2b
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interferon-α-2b (IFN-α-2b)
Study: 26505342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no high-dose IFN-α-2b)
Study: 23868265
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (Control)
Study: 20924615
Drug: NSAID (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (diclofenac sodium, 75 mg/day) and omeprazole (20 mg/day) with placebo
Study: 20924615
Drug: Rebamipide co-therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide co-therapy
Study: 15377321
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg phenazone
Study: 10511067
Drug: Buprenorphine 4
Normalized name: buprenorphine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 4 mg/70 kg
Study: 10511067
Drug: Buprenorphine 8
Normalized name: buprenorphine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 8 mg/70 kg
Study: 10511067
Drug: Higher dosing
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosing regimens (48, 72, 96 hours)
Study: 7489530
Drug: nifedipine-GITS 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine-GITS 30 mg
Study: 7489530
Drug: nifedipine-GITS 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine-GITS 60 mg
Study: 1722967
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose iloprost (0.5 ng/kg/min)
Study: 1722967
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose iloprost (2 ng/kg/min)
Study: 31865326
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (1 strength, 10,000 TU/mL)
Study: 31865326
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (standard, 7 injections with 1,000 TU/mL and 10,000 TU/mL)
Study: 30762267
Drug: Cuminum cyminum
Normalized name: CUMINUM CYMINUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuminum cyminum L. (CuEO) essential oil, 75 mg, thrice daily for 8 weeks
Study: 30762267
Drug: Cuminum cyminum
Normalized name: CUMINUM CYMINUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuminum cyminum L. (CuEO) essential oil
Study: 30762267
Drug: Placebo soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft gel
Study: 27128727
Drug: Psychoeducational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational therapy in addition to routine follow-up